EYEPOINT INC

EyePoint Pharma focuses on breakthrough drug‑device solutions for eye diseases, navigating biotech volatility while aiming to improve patient outcomes worldwide.

EyePoint Pharmaceuticals’ DURAVYU failed in the Phase‑3 LUGANO trial, sparking a 70% share drop and investor fraud investigations—learn how to file a claim and seek recovery.

EyePoint Pharmaceuticals’ Nasdaq stock shows a 4‑fold 52‑week swing, a negative P/E yet strong price‑to‑book ratio—investors eye its eye‑disease drug device pipeline for future profit potential.